Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Oct 29, 2013
Pfizer’s and Merck’s 3Q Performance
Let’s take a look at fundamental performance of Pfizer and Merck during the third quarter. Oct 25, 2013
Surveying 3Q Performance from Big Pharma: Bristol-Myers, Eli Lilly, and AbbVie
Let’s take a look at the third-quarter performance of a few pharmaceutical firms. Aug 5, 2013
Which Sectors Are Leading the Market Higher? And Why Is This Important?
Identifying sector and industry leadership is very important for the institutional money manager as doing so often leads to undervalued firms that are just starting to have their value recognized by the market — Valuentum stocks. Let’s dig into which sectors have been strong and which ones have been weak so far in 2013. Jun 20, 2013
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Big Pharma is not dead, but neither are the generics. Let’s take a look at opportunities presented from patent expiry in the US and low generic utilization rates across the globe. We don’t think investors are expecting the “mountain” of opportunities in 2015. Jun 4, 2013
ASCO Reveals That Big Pharma Is Alive
Some good news from Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Amgen showed the promise of immunotherapies for cancer treatment. Feb 2, 2013
What a Month! Valuentum's February Edition of Its Dividend Growth Newsletter!
The February edition of our Dividend Growth Newsletter is now available! Jan 24, 2013
Bristol-Myers Squibb Beats Estimates
Bristol-Myers is doing a decent job of navigating patent losses. We’re evaluating the firm for addition to the portfolio of our Dividend Growth Newsletter. Dec 11, 2012
Inside AbbVie: A Look at a New Pharmaceutical Giant
Let's take a look at Abbott's new standalone business, AbbVie. Oct 27, 2012
AstraZeneca Is Not Immune to Patent Cliff
AstraZeneca faced revenue and earnings pressure from the loss of exclusivity of Seroquel IR. Still, the firm boasts an impressive pipeline, and management reiterated its full-year earnings guidance. The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
Let's take a look at dividend increases/decreases for the week ending December 20.